Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder in which a substantial number of patients cannot attain treatment target despite antidiabetic drugs. The renin-angiotensin system (RAS) has recently been implicated in the development of insulin resistance and impaired glucose metabolism. This study investigates the effect of adding RAS inhibitors to standard antidiabetic therapy in patients with T2DM. The primary outcome measure is the change in serum glycosylated hemoglobin A1c after 24 weeks of treatment. Secondary outcomes measures include changes in plasma lipid profile and blood pressure after treatment.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
203
Valsartan 80 mg once daily in addition to metformin monotherapy
Metformin monotherapy
Nantou Christian Hospital
Nantou City, Nantou County, Taiwan
Serum glycosylated hemoglobin A1c
Change in serum glycosylated hemoglobin A1c of the participants
Time frame: 24 weeks
Plasma lipid fractions
Change in plasma triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol
Time frame: 24 weeks
Blood pressure
Change in systolic blood pressure and diastolic blood pressure
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.